Analyst Price Targets — ABSI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 25, 2026 10:46 am | — | Morgan Stanley | $10.00 | $10.08 | TheFly | Absci price target raised to $10 from $4.10 at Morgan Stanley |
| June 25, 2026 10:01 am | — | H.C. Wainwright | $16.00 | $10.08 | TheFly | Absci price target raised to $16 from $8 at H.C. Wainwright |
| June 15, 2026 10:40 am | — | Guggenheim | $15.00 | $6.80 | TheFly | Absci price target raised to $15 from $10 at Guggenheim |
| June 4, 2026 10:30 am | — | Leerink Partners | $12.00 | $5.94 | TheFly | Absci initiated with an Outperform at Leerink |
| May 28, 2026 10:39 am | — | BTIG | $9.00 | $5.16 | TheFly | Absci initiated with a Buy at BTIG |
| May 14, 2026 12:01 pm | — | Morgan Stanley | $4.10 | $5.62 | TheFly | Absci price target lowered to $4.10 from $4.20 at Morgan Stanley |
| January 8, 2026 11:14 am | — | Morgan Stanley | $4.32 | $4.02 | TheFly | Absci downgraded to Equal Weight from Overweight at Morgan Stanley |
| December 17, 2025 5:38 pm | — | H.C. Wainwright | $8.00 | $3.44 | TheFly | Absci price target raised to $8 from $7 at H.C. Wainwright |
| March 21, 2024 1:40 pm | Daniel Arias | Stifel Nicolaus | $6.00 | $5.28 | StreetInsider | Absci Corp. (ABSI) PT Raised to $6 at Stifel |
Latest News for ABSI
VANCOUVER, Wash. and NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the second quarter 2026 after market close on Tuesday, August 11, 2026.
The average of price targets set by Wall Street analysts indicates a potential upside of 28.3% in ABSCI CORP (ABSI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Does Absci Corporation (ABSI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Absci stock jumps 36% as interim phase I hair loss study data show ABS-201 is well tolerated and pharmacokinetics support the potential for infrequent dosing.
ABSCI CORP (ABSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ABSI.
U.S. House Trading
No House trades found for ABSI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.